NKGen Biotech Expands Clinical Trial Site Network for Alzheimer's Disease Program Across U.S. to Improve Patient Access and Support Enrollment

New sites in New Jersey, New York, and Florida broaden geographic reach and increase access for patients participating in Phase 2 trial of troculeucel in moderate Alzheimer's disease.